Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Jun 9;27(17):4848–4858. doi: 10.1158/1078-0432.CCR-20-4219

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

©2021 The Authors; Published by the American Association for Cancer Research

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs International 4.0 License.

PMC Copyright notice

Figure 3. Percentage change in pharmacodynamics biomarker levels and association with objective response. *Median percentage changes of biomarker levels at cycle 4, day 1 from baseline are shown at the top of each box plot. Objective response was assessed by mRECIST using independent imaging review. Figures exclude outliers outside the y-axis range: VEGF [lenvatinib complete response/partial response (n = 4; 358.4, 366.1, 393.2, 642.5); lenvatinib noncomplete response/partial response (n = 7; 391.9, 407.7, 467.7, 469.9, 482.7, 526.3, 692.5); sorafenib complete response/partial response (n = 3; 436.0, 475.7, 803.1); sorafenib noncomplete response/partial response (n = 4; 399.9, 461.0, 505.1, 524.3)]; ANG2 [lenvatinib noncomplete response/partial response (n = 2; 132.9, 193.5); sorafenib noncomplete response/partial response (n = 1; 184.4)]; FGF19 [lenvatinib complete response/partial response (n = 6; 614.3, 640.1, 831.4, 1,097.6, 1,233.3, 1,462.5); lenvatinib noncomplete response/partial response (n = 5; 532.8, 533.2, 555.7, 606.7, 843.4); sorafenib noncomplete response/partial response (n = 2; 773.4, 776.6)]; FGF23 [lenvatinib complete response/partial response (n = 1; 258.1); lenvatinib noncomplete response/partial response (n = 1; 207.7)]. All other groups had 0 outliers. ANG2, angiopoietin-2; C, cycle; D, day; FGF, fibroblast growth factor; LEN, lenvatinib; SOR, sorafenib; VEGF, vascular endothelial growth factor. — Percentage change in pharmacodynamics biomarker levels and association with objective response. *Median percentage changes of biomarker levels at cycle 4, day 1 from baseline are shown at the top of each box plot. Objective response was assessed by mRECIST using independent imaging review. Figures exclude outliers outside the y-axis range: VEGF [lenvatinib complete response/partial response (n = 4; 358.4, 366.1, 393.2, 642.5); lenvatinib noncomplete response/partial response (n = 7; 391.9, 407.7, 467.7, 469.9, 482.7, 526.3, 692.5); sorafenib complete response/partial response (n = 3; 436.0, 475.7, 803.1); sorafenib noncomplete response/partial response (n = 4; 399.9, 461.0, 505.1, 524.3)]; ANG2 [lenvatinib noncomplete response/partial response (n = 2; 132.9, 193.5); sorafenib noncomplete response/partial response (n = 1; 184.4)]; FGF19 [lenvatinib complete response/partial response (n = 6; 614.3, 640.1, 831.4, 1,097.6, 1,233.3, 1,462.5); lenvatinib noncomplete response/partial response (n = 5; 532.8, 533.2, 555.7, 606.7, 843.4); sorafenib noncomplete response/partial response (n = 2; 773.4, 776.6)]; FGF23 [lenvatinib complete response/partial response (n = 1; 258.1); lenvatinib noncomplete response/partial response (n = 1; 207.7)]. All other groups had 0 outliers. ANG2, angiopoietin-2; C, cycle; D, day; FGF, fibroblast growth factor; LEN, lenvatinib; SOR, sorafenib; VEGF, vascular endothelial growth factor.